VYNE Therapeutics Inc.
YARW evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $72.1M
- Lead Asset:
- repibresib (Phase 2)
What it means
What to watch
Prepared research question
What matters most for YARW—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · YARW
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and immune-mediated conditions, currently undergoing a strategic review and merger with Yarrow Bioscience.
Key risk: Clinical hold on VYN202
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$72.1M
Cash Runway
—
Lead Asset
repibresib (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for VYNE Therapeutics Inc..
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and immune-mediated conditions, currently undergoing a strategic review and merger with Yarrow Bioscience.
- VYNE is developing VYN202, an oral BD2-selective BET inhibitor for immune-mediated diseases, and repibresib gel (VYN201) for vitiligo, which was discontinued after Phase 2b data [sec_mda · as of 2025-11-06].
- Cash and equivalents were $22.9M as of 2026-06-30, with a net loss of $3.0M for the quarter [sec].
- In August 2025, the board initiated a strategic review to maximize shareholder value, including pipeline assessment and financing opportunities [sec_mda · as of 2025-11-06].
- A merger agreement with Yarrow Bioscience was announced in December 2025, aiming to advance Yarrow's lead program YB-101 for Graves' disease and thyroid eye disease [news · published 2025-12-17].
- VYN202 is under a partial clinical hold for male subjects, with a non-clinical toxicology study in dogs ongoing, expected to complete in the second half of 2026 [sec_mda · as of 2026-05-15].
What works
- VYN202 is designed for high BD2 selectivity, potentially avoiding hematologic and gastrointestinal side effects of earlier BET inhibitors [sec_mda · as of 2025-11-06].
- Repibresib gel has composition of matter patent exclusivity into at least 2042 in the U.S. and 2040 in Europe/Japan, providing long-term protection [sec_mda · as of 2025-11-06].
- The merger with Yarrow Bioscience brings a potentially first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with a planned Phase 1b/2b trial in 2026 [news · published 2025-12-17].
What to weigh
- Repibresib gel's Phase 2b vitiligo trial was terminated after failing to meet primary endpoints, with only modest efficacy on secondary measures [sec_mda · as of 2025-11-06].
- VYN202 is under a partial clinical hold for male subjects, requiring a non-clinical toxicology study that may delay development [sec_mda · as of 2026-05-15].
- The company has a history of net losses and requires significant additional financing to continue operations, with cash runway only into first half of 2027 [news · published 2025-11-06].
- The strategic review and merger introduce uncertainty about the future direction and potential dilution for existing shareholders [sec_mda · as of 2025-11-06].
From the filings
Quoted directly from source documents.
Repibresib gel Phase 2b vitiligo trial was terminated due to lack of efficacy on primary endpoint.
“Based on these data, we discontinued the ongoing extension phase of the trial and has terminated the trial.”
SEC MD&A · November 6, 2025
VYN202 is under a partial clinical hold for male subjects, requiring a 12-week dog toxicology study.
“the clinical hold for two doses of VYN202 for female subjects and indicated that sufficient data from a 12-week non-clinical toxicology study of VYN202 in dogs would be required in order to resume studies in male clinical subjects.”
SEC MD&A · February 27, 2026
Merger with Yarrow Bioscience to advance YB-101 for Graves' disease and thyroid eye disease.
“VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement”
News · December 17, 2025
Cash runway into first half of 2027.
“Cash runway into first half of 2027 based on”
News · November 6, 2025
Risks & what to watch (4)›
Key risks
- Clinical hold on VYN202 — Partial clinical hold for male subjects requires a non-clinical toxicology study, delaying development [sec_mda · as of 2026-05-15].
- Repibresib gel failure — Phase 2b vitiligo trial terminated; seeking external partner for further development [sec_mda · as of 2025-11-06].
- Financing dependency — Requires additional capital to fund operations; cash runway only into first half of 2027 [news · published 2025-11-06].
- Merger execution risk — Integration with Yarrow Bioscience and advancement of YB-101 may face regulatory and clinical hurdles [news · published 2025-12-17].
What to watch
- Completion of the non-clinical toxicology study of VYN202 in dogs, expected in the second half of 2026 [sec_mda · as of 2026-05-15].
- Progress of the merger with Yarrow Bioscience and initiation of the Phase 1b/2b trial for YB-101 in Graves' disease in the first half of 2026 [news · published 2025-12-17].
- Outcome of the strategic review and any financing or partnering announcements [sec_mda · as of 2025-11-06].
- Cash runway updates, as current projections extend into first half of 2027 [news · published 2025-11-06].
Sources: News · SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run VYNE Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VYNE Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.07 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 0.4%
- Days to cover
- 0.6
- Shares short
- 121,535
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
YARW short interestGovernance
Frequently asked questions
What is the AI investment thesis for VYNE Therapeutics Inc.?
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory and immune-mediated conditions, currently undergoing a strategic review and merger with Yarrow Bioscience.
What is VYNE Therapeutics Inc.'s lead drug candidate?
VYNE Therapeutics Inc.'s most advanced tracked candidate is repibresib (Phase 2) for nonsegmental vitiligo (NSV).
Who is the CEO of VYNE Therapeutics Inc.?
Ms. Rebecca Velez Frey Pharm.D. is the chief executive officer of VYNE Therapeutics Inc. (YARW).
Where is VYNE Therapeutics Inc. headquartered?
VYNE Therapeutics Inc. (YARW) is headquartered in New York, NY, United States.
What therapeutic areas does VYNE Therapeutics Inc. focus on?
VYNE Therapeutics Inc. develops therapies across Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.